

Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/UC42357DE3BCEN.html>

Date: March 2022

Pages: 83

Price: US\$ 2,000.00 (Single User License)

ID: UC42357DE3BCEN

Abstracts

Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 11 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Urinary Incontinence - Overview
- Urinary Incontinence - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Urinary Incontinence - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Urinary Incontinence - Companies Involved in Therapeutics Development
- AbbVie Inc
- Cook MyoSite Inc
- Crystec Ltd
- Exopharm Ltd
- Innovacell Biotechnologie AG
- Ixaltis
- Johnson & Johnson
- MUVON Therapeutics AG
- Ningbo Xijian Pharmaceutical Technology Co Ltd
- Orgenesis Inc
- Outpost Medicine Ltd
- Pfizer Inc
- Profem GmbH
- Revance Therapeutics Inc
- RION Health Inc
- Saniona AB
- Sinsin Pharmaceutical Co Ltd
- Taiho Pharmaceutical Co Ltd
- Urovant Sciences Inc
- Versameb AG
- Urinary Incontinence - Drug Profiles
- Biologic for Stress Urinary Incontinence - Drug Profile

Product Description
Mechanism Of Action
Cell Therapy for Stress Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cell Therapy for Urinary Stress Incontinence - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cevaris - Drug Profile
Product Description
Mechanism Of Action
History of Events
EG-017 - Drug Profile
Product Description
Mechanism Of Action
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
History of Events
iltamiocel - Drug Profile
Product Description
Mechanism Of Action
History of Events
litoxetine - Drug Profile
Product Description
Mechanism Of Action
History of Events
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
onabotulinumtoxinA biosimilar - Drug Profile
Product Description
Mechanism Of Action

History of Events

OP-352 - Drug Profile

Product Description

Mechanism Of Action

History of Events

oxybutynin - Drug Profile

Product Description

Mechanism Of Action

Prof-003 - Drug Profile

Product Description

Mechanism Of Action

pVAX-hSlo - Drug Profile

Product Description

Mechanism Of Action

History of Events

Rev-md - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Agonize 5-HT_{2C} for Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate kV7 for Epilepsy, Pain and Urinary Incontinence - Drug Profile

Product Description

Mechanism Of Action

TAS-303 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tolterodine - Drug Profile

Product Description

Mechanism Of Action

tropium chloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

VMB-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Urinary Incontinence - Dormant Projects

Urinary Incontinence - Discontinued Products

Urinary Incontinence - Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

Feb 17, 2022: Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting

Nov 04, 2021: Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference

Dec 17, 2020: FDA grants RMAT designation for Cook MyoSite's investigational autologous Muscle Derived Cells for Urinary Sphincter Repair

Jan 11, 2018: Sleep quality improves with help of incontinence drug

Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Urinary Incontinence

May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego

Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting

Oct 09, 2013: Allergan's BOTOX (Botulinum Toxin Type A) Recommended by the Scottish Medicines Consortium for the Management of Detrusor Overactivity with Urinary Incontinence (Leakage) in Patients with Multiple Sclerosis or Spinal Cord Injury

Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg

Sep 27, 2012: Allergan's Botox Receives UK Authorization For Urinary Leakage In Patients With Multiple Sclerosis Or Spinal Cord Injury

Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference

Dec 05, 2011: Pfizer's Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturnal Urinary Urgency

Aug 30, 2011: Innovacell passes a further milestone

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Urinary Incontinence, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Urinary Incontinence - Pipeline by AbbVie Inc, 2022
Urinary Incontinence - Pipeline by Cook MyoSite Inc, 2022
Urinary Incontinence - Pipeline by Crystec Ltd, 2022
Urinary Incontinence - Pipeline by Exopharm Ltd, 2022
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, 2022
Urinary Incontinence - Pipeline by Ixaltis, 2022
Urinary Incontinence - Pipeline by Johnson & Johnson, 2022
Urinary Incontinence - Pipeline by MUVON Therapeutics AG, 2022
Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2022
Urinary Incontinence - Pipeline by Orgenesis Inc, 2022
Urinary Incontinence - Pipeline by Outpost Medicine Ltd, 2022
Urinary Incontinence - Pipeline by Pfizer Inc, 2022
Urinary Incontinence - Pipeline by Profem GmbH, 2022
Urinary Incontinence - Pipeline by Revance Therapeutics Inc, 2022
Urinary Incontinence - Pipeline by RION Health Inc, 2022
Urinary Incontinence - Pipeline by Saniona AB, 2022
Urinary Incontinence - Pipeline by Sinsin Pharmaceutical Co Ltd, 2022
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
Urinary Incontinence - Pipeline by Urovant Sciences Inc, 2022
Urinary Incontinence - Pipeline by Versameb AG, 2022
Urinary Incontinence - Dormant Projects, 2022
Urinary Incontinence - Dormant Projects, 2022 (Contd..1)
Urinary Incontinence - Dormant Projects, 2022 (Contd..2)
Urinary Incontinence - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Urinary Incontinence, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Urinary Incontinence Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/UC42357DE3BCEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UC42357DE3BCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

